WASHINGTON, Sept 28 (Reuters) - Drugmakers studying experimental drugs in anticipation of U.S. sales must now tell regulators about serious health problems that arise during clinical trials within about two weeks.
WASHINGTON, Sept 28 (Reuters) - Drugmakers studying experimental drugs in anticipation of U.S. sales must now tell regulators about serious health problems that arise during clinical trials within about two weeks.